Ligand Pharmaceuticals to Acquire XOMA Royalty for $739M, Boosting EPS and Diversifying Portfolio

summarizeSummary

Ligand Pharmaceuticals will acquire XOMA Royalty Corporation for $739 million in cash and CVRs, a move expected to immediately boost Ligand's EPS and significantly expand its biopharma royalty portfolio.

check_boxKey Events

• Definitive Acquisition Agreement

  Ligand Pharmaceuticals will acquire XOMA Royalty Corporation for approximately $739 million, comprising $39.00 per share in cash and one non-transferable Contingent Value Right (CVR) per share. The transaction is expected to close in Q3 2026.

• Significant Portfolio Expansion

  The acquisition adds seven new commercial products and over 100 development-stage assets, nearly doubling Ligand's royalty portfolio and enhancing diversification across therapeutic areas.

• Positive Financial Impact & Raised Guidance

  The transaction is expected to be immediately accretive to Ligand's adjusted EPS, with 2026 guidance raised to $8.50-$9.50 and a projected $1.50 per share accretion in 2027.

• Shareholder Support Secured

  Key XOMA Royalty shareholders, including BVF Partners (representing approximately 47% of outstanding shares), have entered into voting agreements in favor of the transaction, increasing the likelihood of approval.

auto_awesomeAnalysis

Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million, consisting of $39.00 per share in cash and one non-transferable Contingent Value Right (CVR) per share. This strategic acquisition, which follows a news announcement earlier today, is expected to be immediately accretive to Ligand's adjusted EPS, with 2026 guidance raised to $8.50-$9.50 and a projected $1.50 per share accretion in 2027. The deal significantly expands Ligand's royalty portfolio by adding seven new commercial products and over 100 development-stage assets, enhancing long-term growth and diversification. The transaction is further solidified by voting agreements from major XOMA Royalty shareholders, including BVF Partners, representing approximately 47% of outstanding shares, which increases the certainty of shareholder approval.